OTCMKTS:IPSEY

Ipsen Stock Forecast, Price & News

$25.67
0.00 (0.00 %)
(As of 07/29/2021 12:00 AM ET)
Add
Compare
Today's Range
$25.67
$25.67
50-Day Range
$25.05
$27.85
52-Week Range
$19.35
$28.10
Volume168 shs
Average Volume3,785 shs
Market Capitalization$8.61 billion
P/E Ratio12.28
Dividend Yield0.75%
Beta1.17
30 days | 90 days | 365 days | Advanced Chart
Receive IPSEY News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.


Ipsen logo

About Ipsen

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents. In addition, it offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. Further, the company provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Comfort, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Additionally, it offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. The company has various agreements with Debiopharm, Exelixis, Galderma, Blueprint Medicines, TerSera Therapeutics, Rhythm Pharmaceuticals, Teijin, Braintree Laboratories, Ethypharm, and Schwabe. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy SA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.06 out of 5 stars

Medical Sector

1255th out of 2,214 stocks

Diagnostic Substances Industry

23rd out of 38 stocks

Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.8Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ipsen (OTCMKTS:IPSEY) Frequently Asked Questions

Is Ipsen a buy right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last year. There are currently 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Ipsen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares.
View analyst ratings for Ipsen
or view top-rated stocks.

What stocks does MarketBeat like better than Ipsen?

Wall Street analysts have given Ipsen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ipsen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ipsen?

Ipsen saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 3,700 shares, an increase of 68.2% from the June 30th total of 2,200 shares. Based on an average daily volume of 4,000 shares, the short-interest ratio is currently 0.9 days.
View Ipsen's Short Interest
.

How has Ipsen's stock price been impacted by COVID-19?

Ipsen's stock was trading at $14.4150 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IPSEY stock has increased by 78.1% and is now trading at $25.67.
View which stocks have been most impacted by COVID-19
.

How often does Ipsen pay dividends? What is the dividend yield for Ipsen?

Ipsen declared a dividend on Tuesday, May 25th. Investors of record on Monday, May 31st will be paid a dividend of $0.5877 per share on Wednesday, June 9th. This represents a dividend yield of 2.21%. The ex-dividend date is Friday, May 28th.
View Ipsen's dividend history
.

Is Ipsen a good dividend stock?

Ipsen pays an annual dividend of $0.19 per share and currently has a dividend yield of 0.75%. The dividend payout ratio of Ipsen is 9.09%. This payout ratio is at a healthy, sustainable level, below 75%.
View Ipsen's dividend history.

Who are Ipsen's key executives?

Ipsen's management team includes the following people:
  • Mr. David Loew, CEO & Director (Age 54, Pay $2.35M)
  • Mr. Aymeric Le Chatelier, Exec. VP & Group CFO (Age 52, Pay $866.2k)
  • Dr. Aidan Murphy, Exec. VP of Technical Operations (Age 55)
  • Ms. Eugenia Litz, VP of Investor Relations
  • Mr. Francois Garnier, Exec. VP & Gen. Counsel (Age 59)
  • Ms. Gwenan White, Exec. VP of Communications Public Affairs
  • Mr. Regis Mulot, Exec. VP & Chief HR Officer (Age 55)
  • Mr. Stephan Gagne, Head of New Tokyo Office
  • Ms. Dominique Laymand, Exec. VP of Ethics & Social Responsibility Officer (Age 67)
  • Mr. Benoit Hennion, Exec. VP of Consumer Healthcare (Age 45)

Who are some of Ipsen's key competitors?

What is Ipsen's stock symbol?

Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY."

How do I buy shares of Ipsen?

Shares of IPSEY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ipsen's stock price today?

One share of IPSEY stock can currently be purchased for approximately $25.67.

How much money does Ipsen make?

Ipsen has a market capitalization of $8.61 billion and generates $3.07 billion in revenue each year. The company earns $625.98 million in net income (profit) each year or $2.09 on an earnings per share basis.

How many employees does Ipsen have?

Ipsen employs 5,700 workers across the globe.

What is Ipsen's official website?

The official website for Ipsen is www.ipsen.com.

Where are Ipsen's headquarters?

Ipsen is headquartered at 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650.

How can I contact Ipsen?

Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The company can be reached via phone at 33-01-58-33-50-00 or via email at [email protected]


This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.